{
  "docId": "019de076-f846-767d-9b7f-8682a04c3e89",
  "docSlug": "d28195e1bb64bc51ad898953c5c30263",
  "documentTitle": "Boundless Bio | IPO Presentation Deck | 51 slides",
  "authorId": "boundless-bio",
  "authorName": "Boundless Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 28,
  "pageCount": 51,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a puzzle piece metaphor to represent the components of a successful therapeutic strategy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f846-767d-9b7f-8682a04c3e89/28",
  "deckHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89",
  "deckJsonHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89.json",
  "deckAnchorHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.62,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "BBI-355 solution puzzle: Potent, selective, oral CHK1i; Proprietary ecDNA diagnostic; Extensive preclinical data; Differentiated clinical design",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52cc53b1-7f80-4019-a90b-7aead1593e9f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.15,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Puzzle pieces representing Potency & ROA, Patient Selection, Robust Preclinical Data, Clinical Strategy",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c48c916-eff9-49da-823e-b69c6b1a8d4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.15,
        "y": 0.7
      },
      "kind": "image",
      "text": "Logos of Sierra Oncology, GSK, Acrivon, Lilly, Merck, AstraZeneca, Genentech",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0316a663-36ea-477e-b838-4ff90bfb54e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.15,
        "y": 0.46
      },
      "kind": "paragraph",
      "text": "Prior CHK1 inhibitors demonstrated clinical anti-tumor activity. However, significant challenges for each: insufficient potency, toxicity, suboptimal ROA, lack of patient selection strategy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8000a1d9-fe88-4cfb-98a8-e774e96a4c97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "BBI-355: novel, selective, oral CHK1 inhibitor designed to disrupt ecDNA and overcome limitations of prior and existing CHK1 inhibitors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f095022e-21fe-4b8b-ba24-5fe178248cb4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "metaphor-analogy",
      "slug": null,
      "matchId": "2e678c1f-b586-4252-ab03-29f0959271dc",
      "evidence": "Uses puzzle pieces to represent the components of a therapeutic strategy.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 28,
      "from": 21,
      "beatId": "402351ce-79f7-45d1-adfe-e111edd1cf9a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents ecDTx as a solution, highlighting the potential of BBI-355 and BBI-825 to address oncogene amplified cancers",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}